ReviewCurrent heart failure reports2026
The Prevention of Heart Failure Risk Assessment and Early Intervention along the Cardiovascular Continuum.
Review in Current heart failure reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewHeart failure (HF) is a complex clinical syndrome that develops as the final common manifestation of diverse cardiovascular disorders along a variety of different pathophysiological pathways. The trajectory towards HF is set decades earlier by a combination of non-modifiable risk factors and a substantial number of principally modifiable risk factors. Conceptualizing HF prevention as a continuum — from primordial prevention to tertiary prevention — highlights how consistently these factors determine and drive the risk to develop HF. Early at-risk and pre-HF stages therefore represent the most appropriate window for effective prevention, yet they are still underrated and under-recognized in clinical practice. RECENT
findingsA broad array of modifiable risk factors, together with echocardiographic and laboratory markers, are involved in disease progression. Combining these domains may optimize risk stratification and enable more targeted prevention efforts. The rapidly evolving heart failure pandemic, largely driven by the rising prevalence of conditions that are to a substantial extent attributable to modifiable risk factors, poses an enormous burden on health systems worldwide. In consequence, enhanced global awareness, comprehensive assessment and more effective control of modifiable risk factors are urgently needed to prevent HF. A multidimensional risk assessment approach could facilitate early identification and timely intervention to prevent progression to symptomatic HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.